SCHEMBL6890761

SCHEMBL6890761

CC(=O)SCCN(CCC1CCCCC1)C(=O)N[C@@H](C)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.39
CASR P41180 1/20 0.36
MCHR1 Q99705 2/20 0.33
GMNN O75496 1/20 0.32
USP2 O75604 1/20 0.32
USP1 O94782 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
POLB P06746 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32
ALOX15 P16050 1/20 0.32
NFKB1 P19838 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.32
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6896738 1.00 LTA4H (0.39) LTA4HCASRMCHR1GMNNUSP2
SCHEMBL27559923 1.00 LTA4H (0.39) LTA4HCASRMCHR1GMNNUSP2
SCHEMBL6894617 1.00 LTA4H (0.39) LTA4HCASRMCHR1GMNNUSP2
SCHEMBL27543525 1.00 LTA4H (0.39) LTA4HCASRMCHR1GMNNUSP2
SCHEMBL6896637 0.99 LTA4H (0.37) LTA4HCASRMCHR1
SCHEMBL27538392 0.99 LTA4H (0.37) LTA4HCASRMCHR1
SCHEMBL6891339 0.98 LTA4H (0.35) LTA4HCASRMCHR1
SCHEMBL27576389 0.98 LTA4H (0.35) LTA4HCASRMCHR1
SCHEMBL6891022 0.94 MCHR1 (0.33) LTA4HMCHR1TP53POLB
SCHEMBL27538287 0.94 MCHR1 (0.33) LTA4HMCHR1TP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
CN-1299344-A Novel urea derivatives SANTEN PHARCEUMATICAL CO LTD (JP) 2001-06-13 CN disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH LTA4H 411/4885CASR 2206/4885MCHR1 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.